Crestline Management LP Purchases 747 Shares of Haemonetics Co. (NYSE:HAE)

Crestline Management LP grew its holdings in shares of Haemonetics Co. (NYSE:HAE) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,801 shares of the medical instruments supplier’s stock after buying an additional 747 shares during the period. Crestline Management LP’s holdings in Haemonetics were worth $453,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. TD Waterhouse Canada Inc. bought a new stake in Haemonetics during the fourth quarter worth about $25,000. Covestor Ltd boosted its position in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the 4th quarter worth approximately $62,000. Parkside Financial Bank & Trust increased its position in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares in the last quarter. Finally, AlphaQuest LLC raised its stake in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

Shares of HAE opened at $68.21 on Friday. The firm has a fifty day simple moving average of $62.75 and a two-hundred day simple moving average of $71.39. The firm has a market cap of $3.43 billion, a PE ratio of 26.85, a P/E/G ratio of 1.11 and a beta of 0.32. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Haemonetics’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.90 earnings per share. On average, equities analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of recent research reports. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. StockNews.com raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Monday, May 5th. JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Raymond James restated a “strong-buy” rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.